相关实验视频
Updated: May 24, 2025

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
BTK抑制剂通过调节激活非GCB扩散大B细胞淋巴瘤细胞中的IL-10/STAT3通路来增强NKG2D连体表达
Zhu-Xia Jia1,2, Bi-Tao Xiao1, Jin Li1
1Department of Hematology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University.
布鲁顿的氨酸激酶 (BTK) 抑制剂在淋巴瘤细胞中的自然杀手组2,成员D (NKG2D) 连接物上调节. IL-10/STAT3通路调节了这种上调,提供了潜在的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 自然杀手组2,成员D (NKG2D) 连接体对于免疫监测至关重要.
- 布鲁顿的氨酸激酶 (BTK) 抑制剂用于治疗B细胞恶性瘤.
- IL-10/STAT3信号通路在BTK抑制剂诱导的NKG2D配体表达中的作用尚未完全理解.
研究的目的:
- 为了研究IL-10/STAT3通路在BTK抑制剂诱导的NKG2D配体 (MICA,ULBP2) 上调中的作用.
- 分析这些影响在非生殖中心的B细胞样扩散大B细胞淋巴瘤 (DLBCL) 细胞中.
主要方法:
- 西方涂抹被用于分析NKG2D连接体表达和IL-10/STAT3通路激活.
- DLBCL细胞系 (SUDHL4,U2932,OCI-LY3) 用BTK抑制剂 (伊布鲁丁尼布,ACP-196,BGB-3111),IgM抗体,一种STAT3抑制剂 (STAT3-IN-1),以及IL-10中和抗体进行治疗.
主要成果:
- BTK 抑制剂增加了 NKG2D 配体的表达,而 IgM 刺激则降低了它.
- 抑制STAT3或IL-10信号导致NKG2D连接体表达的增加.
- 鉴定出IL-10/STAT3通路是BTK抑制剂诱导的NKG2D连接体在U2932和OCI-LY3细胞中的升调的关键调解者.
结论:
- IL-10/STAT3通路对于DLBCL中NKG2D配体的BTK抑制剂介导上调是至关重要的.
- 针对这种途径可以增强用BTK抑制剂治疗的DLBCL患者的抗瘤免疫力.
更多相关视频
05:24Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
相关概念视频
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The JAK-STAT Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...